

CITATION REPORT

List of articles citing

Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection

DOI: 10.1161/circep.120.008662

Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008662.

Source: <https://exaly.com/paper-pdf/76571747/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
250	Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008937	6.4	9
249	Clinical and cardiac characteristics of COVID-19 mortalities in a diverse New York City Cohort. 2020 , 31, 3086-3096		23
248	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients. 2020 , 30, 100637		3
247	COVID-19 infection and cardiac arrhythmias. 2020 , 30, 451-460		49
246	QTc Interval and Mortality in a Population of SARS-2-CoV Infected Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008890	6.4	5
245	Potential Therapeutic Options for COVID-19. 2020 , 2, 89-95		
244	The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. 2020 , 2020, 4312519		16
243	COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. 2021 , 39, 119-139		36
242	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. 2020 , 262, 118541		4
241	The Clinical Utility of Continuous QT Interval Monitoring in Patients Admitted With COVID-19 Compared With Standard of Care: A Prospective Cohort Study. 2020 , 2, 592-598		
240	Cardiac arrest and drug-related cardiac toxicity in the Covid-19 era. <i>Epidemiology, pathophysiology and management</i> . 2020 , 145, 111742		3
239	Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. 2020 , 43, 691-698		59
238	QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019. 2020 , 30, 1482-1485		5
237	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. 2020 , 59, 176-190		44
236	QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. 2020 , 59, 337-345		17
235	Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin. <i>Frontiers in Physiology</i> , 2020 , 11, 587709	4.6	6
234	Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. 2020 , 28, 1760-1776		14

233	A systematic review of ECG findings in patients with COVID-19. 2020 , 72, 500-507	26
232	Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. 2020 , 37, 925-933	12
231	The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review. 2020 , 88, 55	3
230	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis. 2020 , 56, 106212	9
229	Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. 2020 , 173, 287-296	129
228	COVID-19 and sudden cardiac death: A new potential risk. 2020 , 72, 333-336	10
227	Value of electrocardiography in coronavirus disease 2019 (COVID-19). 2020 , 62, 39-45	31
226	Emerging Therapeutic Modalities against COVID-19. <i>Pharmaceuticals</i> , 2020 , 13,	5.2 11
225	HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e0090074	6 6
224	Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. 2020 , 7, 482	22
223	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. 2020 , 13, 945-956	2
222	Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study. 2020 , 60, 328-333	25
221	Physicians' Perspectives on COVID-19: An International Survey. 2020 , 8,	6
220	Innovation in Precision Cardio-Oncology During the Coronavirus Pandemic and Into a Post-pandemic World. 2020 , 7, 145	11
219	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. 2020 , 358, 104240	4
218	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients. 2020 , 11, 582348	11
217	A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. 2020 , 18, 390	21
216	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. 2020 , 11, 562264	5

215	T-wave inversion as a manifestation of COVID-19 infection: a case series. 2020 , 59, 485-493	12
214	Inpatient cardiac monitoring using a patch-based mobile cardiac telemetry system during the COVID-19 pandemic. 2020 , 31, 2803-2811	6
213	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. 2020 , 17, e1003252	55
212	HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. 2020 , 36, 813	4
211	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies. 2020 , 21,	32
210	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. 2020 , 82, 38-47	64
209	Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19. 2020 , 148, 25-33	15
208	Prolonged QT Interval in SARS-CoV-2 Infection: Prevalence and Prognosis. 2020 , 9,	15
207	Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?. 2020 , 7,	10
206	Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review. 2020 , 7, 2049936120947517	9
205	Arrhythmia in COVID-19. 2020 , 2, 1-6	45
204	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. 2020 , 10, 22139	41
203	Absence of relevant QT interval prolongation in not critically ill COVID-19 patients. 2020 , 10, 21417	6
202	Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. 2020 , 8,	26
201	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. 2020 , 37, 100747	11
200	Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19. 2020 , 17, 1445-1451	17
199	Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin. 2020 , 31, 1904-1907	21
198	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. 2020 , 98, 115094	152

197	COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias. 2020 , 17, 1423-1424		11
196	Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update. 2020 , 35, 274-284		18
195	HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. 2020 , 76, 1363-1374		20
194	HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. 2020 , 17, e255-e268		13
193	COVID-19 y arritmias: relación y riesgo. 2020 , 27, 153-159		0
192	Implications of COVID-19 in pediatric rheumatology. 2020 , 40, 1193-1213		26
191	Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. <i>Circulation</i> , 2020 , 142, 513-515	16.7	26
190	Treatment of COVID 19-Repurposing drugs commonly used in dermatology. 2020 , 33, e13829		3
189	COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests. 2020 , 41, 3045-3054		109
188	Natural history of COVID-19 and current knowledge on treatment therapeutic options. 2020 , 129, 110493		59
187	COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not. 2020 , 1298, 167-176		5
186	QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 1090-1097	6.1	21
185	Response to: 'Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?' by Santos-Moreno. 2020 ,		
184	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. 2020 , 16, 659-666		40
183	HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. 2021 , 23, 313		17
182	Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19. 2021 , 7, 16-25		23
181	COVID-19 associated with pulmonary aspergillosis: A literature review. 2021 , 54, 46-53		67
180	Use of hydroxychloroquine for pre-exposure prophylaxis in COVID 19: debate and suggested future course. 2021 , 19, 413-417		9

179	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. 2021 , 46, 17-27	14
178	Pathogenesis-directed therapy of 2019 novel coronavirus disease. 2021 , 93, 1320-1342	22
177	Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. 2021 , 51, e13428	12
176	Hydroxychloroquine/chloroquine and azithromycin in COVID-19 patients: prospective study of electrical parameters. 2021 , 56, 66-68	1
175	Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. 2021 , 75, e13896	8
174	Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. 2021 , 54, e12953	8
173	Decoding the silent walk of COVID-19: Halting its spread using old bullets. 2021 , 133, 110891	1
172	Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions. 2021 , 10, 100-107	12
171	Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. 2021 , 5, 137-150	21
170	Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19. 2021 , 64, 30-35	6
169	Hydroxychloroquine prescribing habits and impact of the COVID-19 pandemic. 2021 , 84, 583-584	
168	Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. 2021 , 893, 173813	14
167	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. 2021 , 53, 117-134	26
166	Recent progress of antiviral therapy for coronavirus disease 2019. 2021 , 890, 173646	16
165	Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic?. 2021 , 102, 389-391	2
164	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. 2021 , 59, 12-23	24
163	The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin. 2021 , 14, 106-112	1
162	Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations. 2021 , 51, 127-138	4

161	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. 2021 , 27, 19-27	144
160	Azithromycin in the treatment of COVID-19: a review. 2021 , 19, 147-163	71
159	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. 2021 , 41, 257-273	0
158	QTc Prolongation in COVID-19 Patients Using Chloroquine. 2021 , 21, 314-321	2
157	COVID-19 and cardiovascular disease: Clinical implications of biochemical pathways. 2021 , 7, 97	1
156	Electrocardiographic markers of increased risk of sudden cardiac death in patients with COVID-19 pneumonia. 2021 , 26, e12824	7
155	Cardiovascular Health and Disease in the Context of COVID-19. 2021 , 12, 67-79	7
154	COVID-19 Outbreak in Italy: Report on the First 124 Consecutive Patients Treated at Home. 2021 , 255, 61-69	0
153	Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes. 2021 , 180, 356-368	7
152	Regarding: "Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019". 2021 , 53, 286	
151	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. 2021 , 28,	11
150	Cardiovascular safety of hydroxychloroquine: Brief appraisal of data. 2021 , 12, 224	
149	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. 2021 ,	28
148	Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS). 2021 , 8, 131-140	4
147	Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients. 2021 , 2021, 6683098	7
146	Association between COVID-19 and Cardiovascular disease. 2021 , 80, 3-5	
145	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. 2021 ,	1
144	and Models to Study SARS-CoV-2 Infection: Integrating Experimental and Computational Tools to Mimic "COVID-19 Cardiomyocyte". <i>Frontiers in Physiology</i> , 2021 , 12, 624185	4.6 4

143	Multimodality diagnosis of cardiac involvement in COVID-19 patients. 2021 , 31, 17-26	0
142	Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings. 2021 , 104, 250-254	51
141	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. 2021 , 35, 101658	2
140	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. 2021 , 12, 607408	10
139	Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey. 2021 , 75, e14182	2
138	Coronavirus disease 2019 (COVID-19) and QTc prolongation. 2021 , 21, 158	8
137	Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions. 2021 , 9,	7
136	Getting to the Heart of the Matter: Myocardial Injury, Coagulopathy, and Other Potential Cardiovascular Implications of COVID-19. 2021 , 2021, 6693895	4
135	Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic. 2021 , 4, e216842	11
134	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. 2021 , 30, 694-706	13
133	Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV-2 main protease. 2021 , 150, 112057	8
132	In-silico clinical trial using high performance computational modeling of a virtual human cardiac population to assess drug-induced arrhythmic risk.	0
131	Challenges Faced by Hospital Pharmacists in Low-Income Countries Before COVID-19 Vaccine Roll-Out: Handling Approaches and Implications for Future Pandemic Roles. 2022 , 19, 232-238	
130	Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis. 2021 , 8,	
129	Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case. 2021 , 23, 1124-1133	2
128	Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study. 2021 , 331, 333-339	7
127	Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19. 2021 , 46, 1308-1311	1
126	Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights. 2021 , 14, 715-734	1

125	Use of hiPSC-derived cardiomyocytes to rule out proarrhythmic effects of drugs: the case of hydroxychloroquine in COVID-19.		
124	Comprehensive Review of Cardiovascular Involvement in COVID-19. 2021 , 32, 169-187		3
123	QT Interval Monitoring with Handheld Heart Rhythm ECG Device in COVID-19 Patients. 2021 , 16, 42		1
122	COVID-19 and Cardiovascular Diseases: Challenges and Solutions. 2021 , 12, 149-155		1
121	Arrhythmogenesis and COVID-19. 2021 , 29, 289-291		3
120	Hydroxychloroquine and Azithromycin Combination in The Management of COVID-19 Infection: Safety and Effectiveness Challenges. <i>Current Drug Safety</i> , 2021 ,	1.4	
119	A review of cardiovascular involvements associated with medications used to treat COVID-19 infection. <i>Cor Et Vasa</i> , 2021 , 63, 359-363	0.3	
118	QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia. 2021 , 37, 1184-1195		0
117	Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial. 2021 ,		1
116	Cardiac arrhythmias in patients presenting with COVID-19 treated in Portuguese hospitals: A national registry from the Portuguese Association of Arrhythmology, Pacing and Electrophysiology. <i>Revista Portuguesa De Cardiologia</i> , 2021 , 40, 573-580	1	5
115	Hydroxychloroquine versus hydroxychloroquine-azithromycin combination therapy on QT interval prolongation of COVID-19 patients: a systematic review and meta-analysis. <i>Cor Et Vasa</i> , 2021 , 63, 475-480 ³		
114	Effects of Hydroxychloroquine and Azithromycin on iPSC-derived Cardiomyocytes: Considerations for the Treatment of COVID-19 Patients.		1
113	QTc prolongation and mortality in SARS-2-CoV-infected patients treated with azithromycin and hydroxychloroquine. 2022 , 23, e21-e23		0
112	Lessons Learned During the Pandemic: Correlation of QT Intervals Between Telemetry and 12-Lead Electrocardiogram. 2021 , 13, e16877		
111	An Umbrella Review of Clinical Efficacy and Adverse Cardiac Events Associated with Hydroxychloroquine or Chloroquine with or Without Azithromycin in Patients with COVID-19. 2021 , 11, e115827		3
110	Electrophysiological and Proarrhythmic Effects of Hydroxychloroquine Challenge in Guinea-Pig Hearts. 2021 , 4, 1639-1653		0
109	Cardiac arrhythmias in patients presenting with COVID-19 treated in Portuguese hospitals: A national registry from the Portuguese Association of Arrhythmology, Pacing and Electrophysiology. 2021 , 40, 573-580		1
108	Safety considerations with new antibacterial approaches for chronic bacterial prostatitis. 2021 , 1-12		

107	. <i>Revista Portuguesa De Cardiologia</i> , 2021 ,	1	1
106	Drug-Induced QTc Prolongation: What We Know and Where We Are Going. <i>Current Drug Safety</i> , 2021 ,	1.4	1
105	Effects of cardiac toxicity of combination therapy with hydroxychloroquine and azithromycin in COVID-19 patients. 2021 , 14, 1668-1670		1
104	Electrocardiographic manifestations of COVID-19: Effect on cardiac activation and repolarization. 2021 , 39, 101057		0
103	Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis. 2021 , 84, 299-316		5
102	Hydroxychloroquine and azithromycin: As a double edge sword for COVID-19?.		0
101	Comparing of the First Electrocardiographic Variables in Patients with Newly Diagnosed COVID-19 with Healthy Men Volunteer: A Systematic Review and Meta-Analysis. 2021 , 50, 46-57		
100	Electrocardiographic Safety of Daily Hydroxychloroquine 400 mg Plus Azithromycin 250 mg as an Ambulatory Treatment for COVID-19 Patients in Cameroon. 2021 , 11, 106-112		
99	Rationale for azithromycin in COVID-19: an overview of existing evidence. 2021 , 8,		23
98	The journey of antimalarial drugs against SARS-CoV-2: Review article. 2021 , 24, 100604		17
97	The value of ECG changes in risk stratification of COVID-19 patients. 2021 , 26, e12815		19
96	Rhythm, conduction, and ST elevation with COVID-19: Myocarditis or myocardial infarction?. 2020 , 6, 671-675		2
95	QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019. 2020 , 1, 167-172		8
94	The Role of Hydroxychloroquine in the Age of COVID-19: A Periodic Systematic Review and Meta-Analysis.		17
93	Concentration-dependent mortality of chloroquine in overdose.		2
92	Mechanistic insights into ventricular arrhythmogenesis of hydroxychloroquine and azithromycin for the treatment of COVID-19.		6
91	Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions. 2020 ,		3
90	Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety: Systematic review of (hydroxy)chloroquine efficacy and safety.		1

89	Chloroquine, but not hydroxychloroquine, prolongs the QT interval in a primary care population.	1
88	Electrocardiographic safety of daily Hydroxychloroquine 400mg plus Azithromycin 250mg as an ambulatory treatment for COVID-19 patients in Cameroon.	2
87	Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea.	5
86	Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19.	8
85	COVID-19 Case Series at UnityPoint Health St. Luke's Hospital in Cedar Rapids, IA.	1
84	Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. 2020 , 17, e1003501	78
83	Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19. 2020 , 12, 604-611	6
82	Use of a Smartwatch for Assessment of the QT Interval in Outpatients with Coronavirus Disease 2019. 2020 , 11, 4219-4222	4
81	A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19. 2020 , 8, 1686	6
80	An Ophthalmic Insight into Novel Coronavirus 2019 Disease: A Comprehensive Review of the Ocular Manifestations and Clinical Hazards. 2020 , 32, 315-328	8
79	Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic. 2020 , 26, 915-922	5
78	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. 2020 , 49,	7
77	Concentration-dependent mortality of chloroquine in overdose. 2020 , 9,	17
76	COVID-19 infection: Disease detection and mobile technology. 2020 , 8, e10345	7
75	The impact of hydroxychloroquine and azithromycin on the corrected qt interval in patients with the novel Coronavirus disease 2019. 2021 , 67, 979-984	0
74	Impact of Hydroxychloroquine Treatment of COVID-19 on Cardiac Conduction: The Beat Goes On. 2021 , 1, 458-464	
73	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. 2021 ,	1
72	The Role of the Immune System on the Cardiac Complications Observed in SARS-CoV-2. 2021 ,	

71	Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. 2021 , 8, 720129	3
70	COVID-19 Prevalence and Outcomes among Individuals with Rheumatoid Arthritis and Systemic Lupus Erythematosus Taking Hydroxychloroquine; A Retrospective Analysis. 2021 , 15, 69-76	1
69	Therapeutic Approach to Coronavirus Disease. 2020 , 67-97	0
68	I. Cloroquina / hidroxiclороquina y azitromicina. Revisi3n narrativa de seguridad. 2020 , 2, 71-82	
67	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.	3
66	Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis.	0
65	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis.	
64	Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.	
63	Electrophysiology in the Era of Coronavirus Disease 2019. 2020 , 9, 167-170	0
62	Prevalence, Outcomes, and Management of Ventricular Arrhythmias in COVID-19 Patients.. 2022 , 14, 11-20	1
61	Cardiac arrhythmias associated with COVID-19 infection: state of the art review. 2021 , 19, 881-889	2
60	Cardiovascular medicine: a year in review. 2021 ,	1
59	Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. 2020 , 01,	1
58	Effects of Hydroxychloroquine With or Without Azithromycin on QT Interval in COVID-19: A Systematic Review. Electrophysiology Collaborative Consortium for Meta-analysis-Electram Investigators. 2020 , Publish Ahead of Print,	
57	A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?. 2021 , 1	1
56	Adverse Drug Reactions During COVID-19 Treatment. 65-71	
55	Predictors of QT Interval Prolongation in Critically-ill Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine.	
54	New psychopharmacotherapy dilemmas associated with COVID-19 [base report. 2020 , 36, 149-153	

53	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. 2020,		1
52	The clinical manifestations and interval changes of reverse-transcriptase quantitative polymerase chain reactions among different specimens of coronavirus disease 2019 patients. 2021, 84, 151-157		0
51	Clinical Evidences and Pathophysiology of Cardiac Arrhythmia in the Era of Coronavirus Disease-2019. 2021, 22, 121-126		
50	Cardiac manifestations of the coronavirus disease-19: a review of pathogenesis, clinical manifestations, diagnosis, and treatment. <i>Pan African Medical Journal</i> , 2021, 39, 173	1.2	
49	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. <i>Journal of Clinical Pharmacology</i> , 2021,	2.9	1
48	Evaluation of the Prognostic Value of the Admission ECG in COVID-19 Patients: A Meta-Analysis. <i>SSRN Electronic Journal</i> ,	1	
47	QTc prolongation in patients with COVID-19: a retrospective chart review.. <i>Translational and Clinical Pharmacology</i> , 2021, 29, 197-205	2	0
46	Comparison of hydroxychloroquine plus moxifloxacin versus hydroxychloroquine alone on corrected QT interval prolongation in COVID-19 patients. <i>Cor Et Vasa</i> , 2021, 63, 564-571	0.3	
45	Interpretable Fuzzy Rule-Based System for Fatal Ventricular Arrhythmia Risk Level Estimation due to QT-Prolonging Treatments*. 2021,		
44	Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association.. <i>Circulation</i> , 2022, CIR0000000000001052	16.7	196
43	High-cited favorable studies for COVID-19 treatments ineffective in large trials.		
42	Temporal change of ventricular repolarization indices and index of cardioelectrophysiological balance (ICEB) during COVID-19 treatment including hydroxychloroquine at a tertiary referral hospital. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 7-12	0	
41	Cardiopulmonary imaging utilization and findings among hospitalized COVID-19 patients in Latin America (From RIMAC: Registry IMAGING Cardiopulmonary among hospitalized COVID-19 patients in LATAM).		
40	Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19.. <i>Frontiers in Physiology</i> , 2021, 12, 730127	4.6	0
39	The QTc interval and treatment outcome of inpatients with COVID-19. <i>PONS - Medicinski Casopis</i> , 2021, 18, 63-73	0	
38	Antimicrobial agents and torsades de pointes. 2022, 231-266		
37	Synergistic Adverse Effects of Azithromycin and Hydroxychloroquine on Human Cardiomyocytes at a Clinically Relevant Treatment Duration.. <i>Pharmaceuticals</i> , 2022, 15,	5.2	1
36	. <i>Revista Portuguesa De Cardiologia</i> , 2022,	1	

35	Associations of pre-existing cardiovascular morbidity with severity and the fatality rate in COVID-19 patients: a systematic review and meta-analysis.. <i>Osong Public Health and Research Perspectives</i> , 2022 , 13, 37-50	6.1	0
34	COVID-19 Cardiovascular Connection: A Review of Cardiac Manifestations in COVID-19 Infection and Treatment Modalities.. <i>Current Problems in Cardiology</i> , 2022 , 101186	17.1	1
33	Coronavirus Disease 2019 and Hypertension: How Anti-Hypertensive Drugs Affect COVID-19 Medications and Vice Versa.. <i>Current Drug Safety</i> , 2022 ,	1.4	
32	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. <i>Journal of Clinical Epidemiology</i> , 2022 ,	5.7	1
31	Hydroxychloroquine alone or in combination with azithromycin and corrected QT prolongation in COVID-19 patients: A systematic review. <i>World Journal of Meta-analysis</i> , 2021 , 9, 557-567	0.5	
30	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , 2021 ,	9.9	3
29	Development of post-COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single hospital retrospective study.. <i>Infezioni in Medicina</i> , 2021 , 29, 538-549	3.6	1
28	Data_Sheet_1.docx. 2020 ,		
27	Data_Sheet_2.docx. 2020 ,		
26	Image_1.tif. 2020 ,		
25	Image_2.TIF. 2020 ,		
24	Image_3.TIF. 2020 ,		
23	Image_4.TIF. 2020 ,		
22	Table_1.doc. 2020 ,		
21	Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation.. <i>Drugs in R and D</i> , 2022 ,	3.4	0
20	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1
19	Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> ,	6.1	1
18	Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. <i>Clinical Rheumatology</i> ,	3.9	2

17	Hydroxychloroquine in a COVID-19 patient on chronic Pregabalin therapy- Is it safe?. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2022 , 38, 127	1.3	1
16	Early Alterations of QTc in Patients with COVID-19 Treated with Hydroxychloroquine or Chloroquine in Libreville, Gabon. <i>Clinics and Practice</i> , 2022 , 12, 482-490	2.4	
15	How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.		0
14	Clinical update of medications associated with QT prolongation among COVID-19 patients. 1-10		
13	Risk of Arrhythmia among New Users of Hydroxychloroquine in RA and SLE : A Population-based Study.		
12	Ventricular Tachycardia or Fibrillation Storm in Coronavirus Disease. 2022 , 2022, 1-9		0
11	Sudden onset of chest pain in SARS-CoV-2 patients: Myocarditis or acute coronary syndrome? A case series. 2022 , 0		0
10	Anti-malarial drugs: mechanisms underlying their proarrhythmic effects.		2
9	Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.		0
8	COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein.		0
7	Further quantitative in silico analysis of SARS-CoV-2 S-RBD Omicron BA.4, BA.5, BA.2.75, BQ.1, and BQ.1.1 transmissibility. 2023 , 254, 124127		1
6	Advances in Cardiac Electrophysiology. 2022 , 15,		1
5	Ethics of Expanded Access During the COVID-19 Pandemic. 2023 , 367-384		0
4	Better safe than sorry Whole-genome sequencing indicates that missense variants are significant in susceptibility to COVID-19. 2023 , 18, e0279356		0
3	Heart Disease and Stroke Statistics 2023 Update: A Report From the American Heart Association.		9
2	Effects of hydroxychloroquine on atrial electrophysiology in in silico wild-type and PITX2+/- atrial cardiomyocytes.		0
1	Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care. 2023 , 11, 790		0